Navigation Links
Nonin Medical als exklusiver Anbieter für zerebrales/somatisches Oximetriesystems an führenden Kinderkliniken in Polen ausgewählt
Date:3/1/2013

mic Compensation™ keine Patientendaten mehr eingegeben werden. Es handelt sich dabei um einen Algorithmus, mit dem das System automatisch Hirngewebe von Neugeborenen und Kindern berücksichtigt. Die Kombination mit dem Dualemitter und dem Dualdetektor, die für absolut präzise Messungen sorgen, machen das EQUANOX-System eindeutig zur besten Wahl."

Der Erwerb des zerebral/somatischen Oximetriesystems EQUANOX von Nonin in Polen wurde vom großen Orchester der Weihnachtshilfe (GOCC) ermöglicht, einer der größten privaten Wohltätigkeitsorganisationen in Polen. Jedes Jahr trifft sich das große Orchester der Weihnachtshilfe mit Krankenhausleitungen, um festzulegen, welches medizinische Gerät am dringendsten gebraucht wird. An zerebral/somatischen Oximetriesystemen besteht in Polen ganz besonders großer Bedarf, da die Ärzte dank dieser Technologie rechtzeitig auf eine Sauerstoffunterversorgung reagieren können, bevor es zu schwerwiegenden Verletzungen kommt. Ziel des GOCC ist es, die Gesundheit und das Leben von Kindern zu schützen, indem es öffentlichen Krankenhäusern medizinische Geräte zu Verfügung stellt.  Seit 1993 hat das GOCC mehr als 100 Millionen USD zum Kauf von medizinischer Ausrüstung in Polen gespendet.

Das EQUANOX Advance-System verwendet das Modell 8004CB und das Modell 8004CB-NA (nichthaftend) der Neonatal/Pädiatrie-Sensoren, um die genaue Sauerstoffsättigung zerebraler und anderer Gewebeteile im Körper zu messen. Die wichtigsten Vorteile des EQUANOX-Systems im Vergleich zu den Geräten der älteren Generationen sind:

  • Zerebrale und somatische Überwachung – Bis zu vier Kanäle auf einem Bildschirm zur Überwachung der Sauerstoffsättigung im Gehirn und in Körperzellen im Körper, darunter die Niere und die Leber
  • Patentierte Se
    '/>"/>

SOURCE Nonin Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nonin Medical Selected as Exclusive Provider of Cerebral/Somatic Oximetry Systems to Leading Pediatric Hospitals in Poland
2. Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health
3. Nonin Medical, Inc. arbeitet bei Pulsoxymetrieangebot für 2net-Plattform für drahtlose Gesundheitslösungen mit Qualcomm Life zusammen
4. Nonin Medical, Inc. Collaborates with Qualcomm Life to Provide Pulse Oximetry for the 2net Platform for Wireless Health Solutions
5. Caliber Imaging & Diagnostics Releases New Products for Noninvasive, Rapid Imaging of Living Cells
6. Masimos Noninvasive Pleth Variability Index as Accurate as Invasive Stroke Volume Variation for Fluid Responsiveness Assessment in Cardiac Surgery
7. Masimo Enters Noninvasive Multigas Monitoring, including Capnography, with Acquisition of PHASEIN
8. Nonin Medical Named Platinum Partner by Tri-anim Health Services
9. Nonin Medicals Tissue Oximetry System Recognized at Premier Healthcare Alliance Innovation Celebration
10. Nonin Medical, Inc. Announces U.S. Market Release of EQUANOX™ Advance Model 8004CB Series Sensor for Neonatal, Pediatric Patients
11. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... , July 30, 2015 Takeda ... the study to fulfill the post-marketing commitment and ... Pan European Multi-Database Bladder Cancer Risk Characterization ... matched cohort study, conducted in four European countries, ... with up to 10 years of follow-up. Findings ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Oct. 28 Horror stories related to medical equipment for ... thousands, even millions of dollars are wasted, and delays in ... www.ecri.org ), an independent nonprofit that researches the best ... equipment issues and 6 best practices to ensure a better ...
... Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical ... sales volumes of the Levulan® Kerastick®, an integral ... platform, surpassed one million units. , "The achievement ... U.S. and abroad continue to embrace Levulan PDT ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent ... Fine, an app invention that can help people during emergencies. , "The worldwide ... CEO and Creative Director of World Patent Marketing. "Currently, there are about 97,000 ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
(Date:7/30/2015)... ... 2015 , ... Mullin/Ashley Associates, Inc. , an integrated ... the Service Industry Advertising Awards 12th annual national competition. , The awards ... University of Maryland Shore Regional Health. , A Gold Award was won by ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects ... editorial and marketing groups will help spread the news about the center’s leading-edge ...
Breaking Medicine News(10 mins):Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... physicians identified six cases of accidental ingestion of wire ... paper calls attention to the need for the public and ... published in the American Journal of Roentgenology and ... Grand, M.D., a radiologist in the diagnostic imaging department at ...
... 28 (HealthDay News) -- Tourists over age 65 who visit malaria-infested ... disease than those ages 18 to 35, a new study says. ... 25,000 U.K. patients also found that the malaria death rate is ... The risk of dying from malaria, an infection carried by mosquitoes, ...
... , WEDNESDAY, March 28 (HealthDay News) -- A drink or ... in the two decades following a heart attack, a new study ... European Heart Journal , included more than 1,800 American men ... were followed for up to 20 years. During that time, 468 ...
... treated with intensity modulated radiation therapy (IMRT) instead of ... of acute or chronic toxicities, according to a study ... the official clinical practice journal of the American Society ... to determine the most effective breast cancer treatment that ...
... Salamon HealthDay Reporter , MONDAY, March 26 (HealthDay ... new study suggests. Those who spend 11 or more hours ... over the next three years regardless of how physically active ... more than 222,000 people aged 45 and older, Australian researchers ...
... 27 (HealthDay News) -- Women with ovarian cancer who ... have annual incomes of less than $35,000 are more ... Researchers found these racial and socioeconomic disparities in ... of surviving for five years after their cancer diagnosis. ...
Cached Medicine News:Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:Older Travelers at Much Higher Risk of Dying From Malaria 2Health News:Moderate Drinking Might Help Men Live Longer After Heart Attack 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Too Much Sitting Can Kill You, Study Suggests 2Health News:Too Much Sitting Can Kill You, Study Suggests 3Health News:Black Women, Uninsured Get Worse Ovarian Cancer Care: Study 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: